Search

Your search keyword '"Haddad, Ghassan"' showing total 143 results

Search Constraints

Start Over You searched for: Author "Haddad, Ghassan" Remove constraint Author: "Haddad, Ghassan" Database Unpaywall Remove constraint Database: Unpaywall
143 results on '"Haddad, Ghassan"'

Search Results

1. Hepatic Radioembolization

2. First-in-human study of 225actinium mti-201 (225Ac-MTI-201) in metastatic uveal melanoma (UM).

6. 629-D The anti-tumor activity of IFNβ and membrane-stable CD40L expressing oncolytic virus MEM-288 in NSCLC patients is associated with modulation of the tumor microenvironment and systemic immune response

8. A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non–small-cell lung cancer (NSCLC).

9. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms

11. Abstract CT103: A phase 1 first-in-human study of MEM-288 oncolytic virus in solid tumors including non-small cell lung cancer (NSCLC): impact on tumor and systemic T cell immunity

12. Figure S3 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

13. Supplemental Data from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

14. Table S4 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

15. Table S1 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

16. Table S4 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

17. Table S2 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

18. Table S2 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

19. Table S5 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

20. Table S3 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

21. Supplemental Data from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

22. Table S3 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

23. Table S5 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

24. Figure S2 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

25. Table S1 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

26. Developing a novel patient-reported outcome measure for patients with prostate cancer receiving radionuclide therapy: The FACT-RNT.

27. 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE

28. Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer

30. 1132 Impact of intralesional oncolytic viral therapy targetingin situactivation of CD40 and type 1 interferon signaling pathways on the TME and systemic T cell immunity in murine models and cancer patients

37. [177Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial.

42. Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study

45. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

46. Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study

Catalog

Books, media, physical & digital resources